Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINYSE:CVMNYSE:MBXNASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$2.06+2.0%$1.47$1.03▼$2.57$412.70M1.221.58 million shs1.71 million shsCVMCEL-SCI$2.51+2.0%$7.09$2.32▼$66.60$228.50M0.549,893 shs715,232 shsMBXMBX Biosciences$12.15-2.9%$8.93$4.81▼$27.50$406.10MN/A252,439 shs198,240 shsMDCXMedicus Pharma$7.29+3.0%$4.37$1.80▼$8.94$98.38MN/A83,448 shs142,672 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences+1.98%+24.85%+35.53%+3.52%+23.35%CVMCEL-SCI+2.03%-62.48%-70.87%-78.87%-93.51%MBXMBX Biosciences-2.88%+8.87%+35.15%+11.67%+1,214,999,900.00%MDCXMedicus Pharma+2.97%+8.32%+85.97%+82.25%+728,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.2985 of 5 stars3.71.00.00.02.52.50.6CVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.7982 of 5 stars3.50.00.00.02.93.30.6MDCXMedicus Pharma1.6827 of 5 stars3.80.00.00.02.40.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.33Buy$8.67320.71% UpsideCVMCEL-SCI 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.50208.64% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50222.36% UpsideCurrent Analyst Ratings BreakdownLatest MDCX, ATAI, CVM, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/20/2025ATAIAtai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIAtai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/14/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/10/2025MBXMBX BiosciencesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$1.86M221.52N/AN/A$1.47 per share1.40CVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.91N/AN/AN/AN/A-65.75%-52.71%8/12/2025 (Estimated)CVMCEL-SCI-$26.92M-$0.42N/AN/AN/AN/A-238.05%-104.65%N/AMBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/A0.00N/AN/AN/AN/AN/A6/27/2025 (Estimated)Latest MDCX, ATAI, CVM, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ATAIAtai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81CVMCEL-SCI0.661.071.09MBXMBX BiosciencesN/AN/AN/AMDCXMedicus PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%CVMCEL-SCI12.08%MBXMBX BiosciencesN/AMDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%CVMCEL-SCI9.93%MBXMBX Biosciences52.19%MDCXMedicus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80200.34 million115.45 millionOptionableCVMCEL-SCI4391.04 million64.67 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/AMDCXMedicus PharmaN/A13.50 millionN/AN/AMDCX, ATAI, CVM, and MBX HeadlinesRecent News About These CompaniesMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22 at 10:05 AM | proactiveinvestors.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22 at 9:59 AM | proactiveinvestors.comMedicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)May 22 at 7:30 AM | newsfilecorp.comMedicus Pharma Ltd. (NASDAQ:MDCX) Major Shareholder Velocity Fund Partners, Lp Sells 75,000 SharesMay 22 at 7:20 AM | insidertrades.comMedicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Misses Estimates By $0.19 EPSMay 14, 2025 | marketbeat.comD. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00May 14, 2025 | marketbeat.comMedicus Pharma LtdMay 14, 2025 | cnn.comMedicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00May 14, 2025 | americanbankingnews.comMedicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial PortfolioMay 12, 2025 | benzinga.comMedicus Pharma Ltd. plans strategic acquisitionMay 10, 2025 | pottsmerc.comMedicus Pharma to acquire Antev in strategic biotech dealApril 30, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Earns "Buy" Rating from D. Boral CapitalApril 30, 2025 | marketbeat.comMedicus Pharma signs letter of intent to buy British biotech companyApril 29, 2025 | bizjournals.comMedicus Pharma Ltd (MDCX)April 29, 2025 | investing.comMedicus to buy Antev for $75 millionApril 29, 2025 | thepharmaletter.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange TransactionApril 28, 2025 | finance.yahoo.comMedicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentApril 28, 2025 | proactiveinvestors.comMedicus Pharma to Acquire Antev Ltd. in $75 Million DealApril 28, 2025 | tipranks.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.April 28, 2025 | newsfilecorp.comMedicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma TreatmentApril 21, 2025 | tipranks.comMedicus Pharma expands basal cell carcinoma study after encouraging early dataApril 21, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, ATAI, CVM, and MBX Company DescriptionsAtai Life Sciences NASDAQ:ATAI$2.06 +0.04 (+1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.09 +0.03 (+1.46%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.CEL-SCI NYSE:CVM$2.51 +0.05 (+2.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.54 +0.04 (+1.39%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.MBX Biosciences NYSE:MBX$12.15 -0.36 (-2.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$12.15 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Medicus Pharma NASDAQ:MDCX$7.29 +0.21 (+2.97%) As of 05/23/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
